What is Cingulate?
Cingulate is a clinical-stage biopharmaceutical company dedicated to enhancing patient lives through its proprietary Precision Timed Release drug delivery platform. Established in 2012 and headquartered in Kansas City, Kansas, the company focuses on developing next-generation pharmaceutical products for frequently diagnosed conditions. Cingulate aims to address the challenges of burdensome daily dosing regimens and suboptimal treatment outcomes, offering improved therapeutic solutions.
How much funding has Cingulate raised?
Cingulate has raised a total of $26.3M across 6 funding rounds:
Private Equity
$6.8M
Private Equity
$7.5M
Debt
$150K
Debt
$237K
Share Placement
$5M
Debt
$6.6M
Private Equity (2013): $6.8M, investors not publicly disclosed
Private Equity (2018): $7.5M led by Werth Family Investment Associates
Debt (2020): $150K supported by PPP
Debt (2021): $237K featuring PPP
Share Placement (2024): $5M, investors not publicly disclosed
Debt (2025): $6.6M, investors not publicly disclosed
Key Investors in Cingulate
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Cingulate?
With the recent major enterprise-level funding and strategic investment, Cingulate is poised for significant advancements. This capital injection is expected to accelerate the development and commercialization of its pipeline products. The company's focus on improving patient compliance and treatment efficacy through its innovative drug delivery technology positions it for substantial growth and market impact in the biopharmaceutical sector. Future endeavors will likely concentrate on clinical trial progression and strategic partnerships to broaden its therapeutic reach.
See full Cingulate company page
